Literature DB >> 21072898

Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.

Hiroaki Nema1, Mototsugu Kato.   

Abstract

AIM: To compare the therapeutic effects of proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) on gastroduodenal ulcers under continuous use of low-dose aspirin.
METHODS: Sixty patients who had a gastroduodenal ulcer on screening endoscopy but required continuous use of low-dose aspirin were randomly assigned to receive PPI (lansoprazole 30 mg, n = 30) or H2RA (famotidine 40 mg or if famotidine had been administered before assignment, ranitidine 300 mg, n = 30). The therapeutic effects were evaluated by endoscopy after 8-wk treatment. The presence or absence of Helicobacter pylori (H. pylori) was determined by urea breath test before treatment. Abdominal symptoms were compared with the gastrointestinal symptom rating scale (GSRS) questionnaire before and after treatment.
RESULTS: Twenty-six patients in the PPI group and 26 patients in the H2RA group, excluding dropouts, were analyzed. There were no significant differences in median age, sex, underlying disease, smoking status, H. pylori infection, prevalence of ulcers before treatment, and lesion site between the two groups. The therapeutic effects were endoscopically evaluated as healed in 23 patients (88.5%) and not healed in 3 patients in the PPI group and as healed in 22 patients (84.6%) and not healed in 4 patients in the H2RA group. Abdominal symptoms before treatment were uncommon in both groups; the GSRS scores were not significantly reduced after treatment as compared with before treatment.
CONCLUSION: The healing rate of gastroduodenal ulcers during continuous use of low-dose aspirin was greater than 80% in both the PPI group and the H2RA group, with no significant difference between the two groups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21072898      PMCID: PMC2980684          DOI: 10.3748/wjg.v16.i42.5342

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.

Authors:  N M Agrawal; D R Campbell; M A Safdi; N L Lukasik; B Huang; M M Haber
Journal:  Arch Intern Med       Date:  2000-05-22

2.  Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding.

Authors:  A Lanas; E Bajador; P Serrano; J Fuentes; S Carreño; J Guardia; M Sanz; M Montoro; R Sáinz
Journal:  N Engl J Med       Date:  2000-09-21       Impact factor: 91.245

3.  A statistical evaluation on the age and sex distribution of basal serum gastrin and gastric acid secretion in subjects with or without peptic ulcer disease.

Authors:  H Tahir; K Sumii; K Haruma; A Tari; N Uemura; H Shimizu; M Sumioka; Y Inaba; T Kumamoto; Y Matsumoto
Journal:  Hiroshima J Med Sci       Date:  1984-06

4.  Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans.

Authors:  B Cryer; M Feldman
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

5.  Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan.

Authors:  S Ohara; M Kato; M Asaka; T Toyota
Journal:  J Gastroenterol       Date:  1998-02       Impact factor: 7.527

6.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

Authors:  N D Yeomans; Z Tulassay; L Juhász; I Rácz; J M Howard; C J van Rensburg; A J Swannell; C J Hawkey
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

7.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.

Authors:  Jan van Gijn; Ale Algra; Jaap Kappelle; Peter J Koudstaal; Anet van Latum
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

8.  Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.

Authors:  Donald R Campbell; Marian M Haber; Eric Sheldon; Cyndy Collis; Nancy Lukasik; Bidan Huang; Jay L Goldstein
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

9.  Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.

Authors:  Luis Alberto García Rodríguez; Sonia Hernández-Díaz
Journal:  Am J Epidemiol       Date:  2004-01-01       Impact factor: 4.897

10.  Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in Occidental and Oriental duodenal ulcer patients.

Authors:  M Feldman; C T Richardson; S K Lam; I M Samloff
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

View more
  11 in total

Review 1.  Gastrointestinal effects of aspirin.

Authors:  Carlos Sostres; Angel Lanas
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

2.  Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.

Authors:  Tsuyoshi Sanuki; Tsuyoshi Fujita; Hiromu Kutsumi; Takanobu Hayakumo; Shun-ichi Yoshida; Hideto Inokuchi; Manabu Murakami; Yoshihiro Matsubara; Hajime Kuwayama; Takashi Kawai; Hideki Miyaji; Takashi Fujisawa; Shuichi Terao; Yukinao Yamazaki; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-04-17       Impact factor: 7.527

Review 3.  Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy.

Authors:  Junichi Iwamoto; Yoshifumi Saito; Akira Honda; Yasushi Matsuzaki
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

4.  Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications.

Authors:  Ling-Ling Zhu; Ling-Cheng Xu; Yan Chen; Quan Zhou; Su Zeng
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

5.  PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis.

Authors:  Chen Mo; Gang Sun; Yan-Zhi Wang; Ming-Liang Lu; Yun-Sheng Yang
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Does Helicobacter pylori Exacerbate Gastric Mucosal Injury in Users of Nonsteroidal Anti-Inflammatory Drugs? A Multicenter, Retrospective, Case-Control Study.

Authors:  Yoshiyasu Kono; Hiroyuki Okada; Ryuta Takenaka; Ko Miura; Hiromitsu Kanzaki; Keisuke Hori; Masahide Kita; Takao Tsuzuki; Seiji Kawano; Yoshiro Kawahara; Kazuhide Yamamoto
Journal:  Gut Liver       Date:  2016-01       Impact factor: 4.519

Review 7.  Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits.

Authors:  Kok Ann Gwee; Vernadine Goh; Graca Lima; Sajita Setia
Journal:  J Pain Res       Date:  2018-02-14       Impact factor: 3.133

8.  The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries.

Authors:  Jing Zhao; Yihong Fan; Wu Ye; Wen Feng; Yue Hu; Lijun Cai; Bin Lu
Journal:  Gastroenterol Res Pract       Date:  2019-06-18       Impact factor: 2.260

9.  A possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats.

Authors:  Ho-Jae Lee; Young-Min Han; Eun-Hee Kim; Yoon-Jae Kim; Ki-Baik Hahm
Journal:  BMC Gastroenterol       Date:  2012-10-16       Impact factor: 3.067

Review 10.  Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.

Authors:  Robert Andrew Moore; Sheena Derry; Lee S Simon; Paul Emery
Journal:  Pain Pract       Date:  2013-08-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.